MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Apellis Pharmaceuticals Inc

Închisă

SectorSănătate

19.46 -3.09

Rezumat

Modificarea prețului

24h

Curent

Minim

19.19

Maxim

19.73

Indicatori cheie

By Trading Economics

Venit

-56M

-92M

Vânzări

-46M

167M

Marjă de profit

-55.292

Angajați

705

EBITDA

-56M

-80M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+85.88% upside

Dividende

By Dow Jones

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-54M

2.5B

Deschiderea anterioară

22.55

Închiderea anterioară

19.46

Sentimentul știrilor

By Acuity

71%

29%

339 / 376 Clasament în Healthcare

Apellis Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 iul. 2025, 21:01 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 20:46 UTC

Câștiguri

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 iul. 2025, 20:39 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 20:36 UTC

Câștiguri

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 iul. 2025, 20:16 UTC

Achiziții, Fuziuni, Preluări

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 iul. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 iul. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 iul. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 iul. 2025, 18:24 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 iul. 2025, 18:19 UTC

Câștiguri

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 iul. 2025, 18:11 UTC

Achiziții, Fuziuni, Preluări

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 iul. 2025, 18:11 UTC

Câștiguri

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 iul. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 iul. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 iul. 2025, 16:28 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 16:04 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 iul. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 iul. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 iul. 2025, 15:47 UTC

Market Talk
Câștiguri

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparație

Modificare preț

Apellis Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

85.88% sus

Prognoză pe 12 luni

Medie 37.25 USD  85.88%

Maxim 60 USD

Minim 17 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruApellis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

10

Cumpărare

7

Păstrare

0

Vânzare

Sentiment

By Acuity

339 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.